Real‐World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Nicola Perrotta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy has significantly improved clinical outcomes in people with cystic fibrosis (PwCF) carrying at least one Phe508del CFTR mutation. However, real‐world evidence on the safety and effectiveness of ETI in pediatric populations remains limited, particularly in children with more severe disease phenotypes who are often excluded from clinical trials. We analyzed clinical, functional, and microbiological data from pediatric CF patients aged 6–17 years treated with ETI between October 2022 and March 2024. Lung function (ppFEV 1 , ppFVC), nutritional status (BMI, BMI z ‐score), sweat chloride concentration (SwCl), quality of life (CFQ‐R), pulmonary exacerbations (PEx), and airway pathogens were assessed at baseline and after 6–12 months. Adverse events (AEs) and therapy discontinuations were also recorded. Twenty‐four patients ( n = 10 aged 6–11 years; n = 14 aged 12–17 years) were included. At 12 months, mean ppFEV 1 increased by 15% ( p = 0.013), BMI by 2.4 kg/m 2 ( p = 0.16), BMI weight z‐score by 0.33 ( p = 0.63), and height z ‐score by −0.33 ( p = 0.72), SwCl decreased by 46 mmol/L ( p < 0.001), and CFQ‐R respiratory domain improved by 14 points ( p < 0.001). PEx rates decreased by 27.6% after 12 months. Reductions in airway pathogen prevalence, particularly Staphylococcus aureus and Pseudomonas aeruginosa , were observed. AEs occurred in 14.8% ( n = 4) of patients, were mild‐to‐moderate, and resolved with dose reduction. ETI therapy was associated with marked improvements in lung function, nutritional status, and quality of life, along with reductions in PEx and airway pathogens, in a real‐world pediatric CF cohort. These findings support ETI use in this population, with careful AE monitoring and dose adjustment when needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy.
- Pharmacy Unit, AOU Policlinico Umberto I - Sapienza University, Rome, Italy.
- Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy.
- Biostatistics Unit, GIMEMA Foundation, Rome, Italy.
- Regional Cystic Fibrosis Center, AOU Policlinico Umberto I - Sapienza University, Rome, Italy.
- Clinical Research Unit, AOU Policlinico Umberto I - Sapienza University, Rome, Italy.
ORCID-Profile: Nicola Perrotta
Zitieren
APA
Perrotta, N., Fiorito, L. A., Gentile, R., Vescovo, R., Piciocchi, A., Troiani, P., Poscia, R., & Cimino, G. (2025). Real‐World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70373
Vancouver
Perrotta N, Fiorito LA, Gentile R, Vescovo R, Piciocchi A, Troiani P, et al. Real‐World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study. Clinical and Translational Science. 2025. doi:10.1111/cts.70373
BibTeX
@article{Perrotta2025,
author = {Perrotta, Nicola and Fiorito, Luigi Angelo and Gentile, Rossella and Vescovo, Roberta and Piciocchi, Alfonso and Troiani, Patrizia and Poscia, Roberto and Cimino, Giuseppe},
title = {Real‐World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70373}
}
EUVIMED